Economic Observation Network The core pipeline of Yasheng Pharmaceutical has recently received positive signals from the management, with clear information on the development and registration of its products.

Business progress:
Recently, the management has released positive signals regarding the core pipelines (Orebutinib, Risatocla), including FDA communication, accelerated approval pathways, and a clear global registration schedule, actively eliminating market information gaps Especially the exclusive advantage of Lysatokla in the blank track of HR-MDS has become an important source of expectation gap 。

The above content is based on publicly available information and does not constitute investment advice.